Quark Pharmaceuticals (Fremont, CA) development-stage pharmaceutical company focused on discovering and developing novel RNAi therapeutics, closed a $27M Series B financing. Participants include SBI Investment Co.
Traversa Therapeutics (La Jolla, CA) a discovery and development stage focused on RNAi delivery closed a $2M Series A financing. Participants include San Diego Tech Coast Angels, Mesa Verde Venture Partners and Morningside Group.